Prolongation of concordant xenograft survival by treatment with FTY720.
Miyata
Y
Y
Second Department of Surgery, Hiroshima University, School of Medicine, Japan.
Ohdan
H
H
Noriyuki
T
T
Shintaku
S
S
Shibata
S
S
Yamamoto
H
H
Fan
X H
XH
Fudaba
Y
Y
Yoshioka
S
S
Asahara
T
T
Fukuda
Y
Y
Dohi
K
K
D000284:Administration, Oral; D000818:Animals; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology; D006224:Cricetinae; D000068876:Fingolimod Hydrochloride; D006085:Graft Survival / Q000187:drug effects*; D016027:Heart Transplantation / Q000276:immunology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D016031:Liver Transplantation / Q000276:immunology*; D008212:Lymphocyte Depletion; D008647:Mesocricetus; D011409:Propylene Glycols / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D011917:Rats, Inbred Lew; D016038:Skin Transplantation / Q000276:immunology*; D013110:Sphingosine / Q000031:analogs & derivatives; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D014183:Transplantation, Heterologous / Q000276:immunology*
D007166:Immunosuppressive Agents; D011409:Propylene Glycols; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine